...
首页> 外文期刊>Glioma >Clinical value of neuronavigation combined with a fluorescent staining technique during microsurgery for treating supratentorial glioma: A case-control observational study
【24h】

Clinical value of neuronavigation combined with a fluorescent staining technique during microsurgery for treating supratentorial glioma: A case-control observational study

机译:神经元疫苗临床价值联合荧光染料技术在微外科治疗术后胶质瘤中的荧光染色技术:一种案例控制观测研究

获取原文

摘要

Background and Aim: Many studies have demonstrated the value of neuronavigation guided by fluorescence staining for treating glioma patients. Here, we compared the rate of overall survival (OS) and the extent of tumor resection among patients who underwent surgery with neuronavigation and fluorescence versus conventional techniques. Materials and Methods: In this case-control observational study, data from 162 patients with supratentorial glioma who underwent surgery from January 2016 to November 2017 were retrospectively analyzed, including a neuronavigation and fluorescence treatment group (combined group, n = 53) and a conventional microsurgery group (control group, n = 109). The extent of tumor resection, World Health Organization (WHO) pathological grade, eloquent areas involved, tumor diameter, preoperative Karnofsky Performance Status score, underlying diseases, chemotherapy, hospitalization days, length of operation, intraoperative blood loss, and postoperative molecular pathological indictors were recorded. OS rates were compared using the Cox proportional hazards regression model. The study was approved by the Ethics Committee of Zhongnan Hospital of Wuhan University (approval No. 2019048). Results: The total resection rate was 60.4% in the combined group and 27.5% in the control group. Multivariate logistic regression analysis revealed that involvement of eloquent areas (odds ratio [OR] = 0.455, 95% confidence interval [CI]: 0.214–0.966, P = 0.040) and the use of the combined technique (OR = 3.634, 95% CI: 1.758–7.510, P 0.001) were independent prognostic factors affecting total glioma resection. Eloquent areas were implicated in 79 patients. Multiple logistic regression analysis revealed that the combined technique (OR = 6.041, 95% CI: 1.705–21.403, P = 0.005) was an independent prognostic factor affecting total resection. The average follow-up period was 16.4 months. Cox regression analysis revealed that the WHO tumor grade (hazard ratio [HR] = 4.782, 95% CI: 1.620-14.119, P = 0.005), chemotherapy regimen (HR = 0.324, 95% CI: 0.181–0.579, P 0.001), IDH mutation (HR = 0.366, 95% CI: 0.154–0.870, P = 0.023), and total resection (HR = 0.458, 95% CI: 0.248–0.846, P = 0.013) were independent factors affecting the prognosis of glioma patients. Conclusions: The use of neuronavigation with fluorescent staining appears to improve the tumor resection range and the OS rate, which is an independent factor affecting the degree of resection of supratentorial glioma. The WHO tumor grade, chemotherapy regimen, IDH mutation, and total resection were independent factors affecting the prognosis of glioma patients.
机译:背景和目的:许多研究表明,通过荧光染色来治疗胶质瘤患者的荧光染色引导的神经辐射的价值。在这里,我们比较了整体存活率(OS)的速率以及接受神经通脉和荧光与常规技术进行手术的患者中的肿瘤切除程度。材料和方法:在本病例控制的观察性研究中,回顾性分析了来自2016年1月至2017年11月的手术的162例患有术治疗症的数据,包括神经道抗原和荧光治疗组(联合组,N = 53)和常规显微外科群(对照组,N = 109)。肿瘤切除程度,世界卫生组织(世卫组织)病理级,涉及雄性地区,肿瘤直径,术前karnofsky性能状况得分,潜在疾病,化疗,住院日,操作长度,术中失血和术后分子病理指示记录。使用Cox比例危险回归模型进行比较OS率。该研究得到了武汉中南医院伦理委员会批准(批准No.2019048)。结果:组合组总切除率为60.4%,对照组27.5%。多变量逻辑回归分析显示,雄性区域的参与(差距[或] = 0.455,95%置信区间[CI]:0.214-0.966,P = 0.040)和组合技术(或= 3.634,95%CI)的使用:1.758-7.510,P <0.001)是影响总胶质瘤切除术的独立预后因素。雄辩的区域涉及79名患者。多重逻辑回归分析显示,组合技术(或= 6.041,95%CI:1.705-21.403,P = 0.005)是影响总切除术的独立预后因素。平均随访时间为16.4个月。 Cox回归分析显示,世卫组织肿瘤级(危害比[HR] = 4.782,95%CI:1.620-14.119,P = 0.005),化疗方案(HR = 0.324,95%CI:0.181-0.579,P <0.001 ),IDH突变(HR = 0.366,95%CI:0.154-0.870,P = 0.023)和总切除(HR = 0.458,95%CI:0.248-0.846,P = 0.013)是影响胶质瘤预后的独立因素耐心。结论:使用荧光染色的神经道抗原似乎改善肿瘤切除范围和OS率,这是影响超前胶质瘤切除程度的独立因素。世卫组织肿瘤级,化疗方案,IDH突变和总切除是影响胶质瘤患者预后的独立因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号